Teva Pharmaceuticals voluntarily recalled more than half a million bottles of prazosin hydrochloride after testing detected N‑nitroso prazosin impurity C above acceptable intake limits. The FDA classified the recall as Class II; nitrosamine impurities have previously triggered major hypertension‑drug recalls and regulatory scrutiny. Teva flagged lot‑level manufacturing or storage issues as potential causes and will need to work with regulators and supply‑chain partners to contain shortages and restore market confidence.